Aktis' most advanced program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Strong, demonstrated workplace skills, including but not limited to: time management - schedules, timelines, task prioritization; communication - written and verbal; ability to coordinate and interact with all levels and functions; analytical and organizational.